By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation) 

US LOCATION:
3805 Old Easton Road
Doylestown, PA 18902

CAN LOCATION:
8900 Glenlyon Parkway

Burnaby,  British Columbia,  V5J 5J8  Canada
Phone: 604-419-3200 Fax: 604-419-3201


SEARCH JOBS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.


Key Statistics


Email: careers@arbutusbio.com
Ownership: Public

Web Site: Arbutus Biopharma
Employees: <500 Employees
Symbol: ABUS
 









Company News
Arbutus Biopharma (ABUS) Provides Corporate Update And Announces First Quarter 2016 Financial Results 5/5/2016 8:17:11 AM
Arbutus Biopharma (ABUS) Expands HBV Pipeline 5/4/2016 7:48:38 AM
Arbutus Biopharma (ABUS) To Provide A Corporate Update And Release First Quarter 2016 Financial Results 4/29/2016 10:21:14 AM
Arbutus Biopharma (ABUS) To Participate In Upcoming Investor Conferences 4/28/2016 8:13:00 AM
Arbutus Biopharma (ABUS) Presents Data From Combination Activity Studies Of HBV Drug Candidates 4/22/2016 8:27:10 AM
Arbutus Biopharma (ABUS) Announces Planned Executive Departure 4/22/2016 8:25:41 AM
Arbutus Biopharma (ABUS) Presents Data On HBV Capsid Assembly Inhibitor AB-423 At EASL 2016 4/14/2016 8:04:11 AM
Arbutus Biopharma (ABUS) To Present Preclinical HBV Data At EASL 2016 3/31/2016 10:46:22 AM
Arbutus Biopharma (ABUS) Announces Year-End 2015 Financial Results 3/9/2016 8:05:03 AM
Arbutus Biopharma (ABUS) Appoints Dr. Elizabeth Howard Executive Vice President And General Counsel 3/8/2016 8:09:03 AM
12345678910...
//-->